Dunn, Billy

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 10,537

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 2,803

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation

Statistical Methods in Clinical TrialsPharmacovigilance and Adverse Drug Reactions

Cited by 750

Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective

Dunn, B., Stein, P., & Cavazzoni, P. (2021) · JAMA Internal Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 246

An Appropriate Use of Accelerated Approval — Aducanumab for Alzheimer’s Disease

Dunn, B., Stein, P., Temple, R., & Cavazzoni, P. (2021) · New England Journal of Medicine

Alzheimer's disease research and treatmentsBiomedical Ethics and Regulation

Cited by 42